Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Anti-viral action against type 1 diabetes autoimmunity : The GPPAD-AVAnT1A study protocol

Hummel, Sandra ; Käßl, Alexandra ; Arnolds, Stefanie ; Achenbach, Peter ; Berner, Reinhard ; Casteels, Kristina ; Hyöty, Heikki ; Kordonouri, Olga ; Larsson, Helena Elding LU orcid and Lundgren, Markus LU , et al. (2025) In Contemporary Clinical Trials Communications 44.
Abstract

Viral infections in the first year of life are associated with islet autoimmunity and type 1 diabetes risk. The Anti-Viral Action against Type 1 Diabetes Autoimmunity (AVAnT1A)- study is a clinical phase IV investigator initiated, randomised, controlled, multicentre, primary prevention trial conducted to determine whether vaccination against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in children with elevated genetic risk. Additionally, it investigates the role of viral infections in the etiology of islet autoimmunity by intense surveillance within the first two years of life. Infants aged 3.00-4.00 months from Germany, Belgium, UK and Sweden are eligible if they have a... (More)

Viral infections in the first year of life are associated with islet autoimmunity and type 1 diabetes risk. The Anti-Viral Action against Type 1 Diabetes Autoimmunity (AVAnT1A)- study is a clinical phase IV investigator initiated, randomised, controlled, multicentre, primary prevention trial conducted to determine whether vaccination against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in children with elevated genetic risk. Additionally, it investigates the role of viral infections in the etiology of islet autoimmunity by intense surveillance within the first two years of life. Infants aged 3.00-4.00 months from Germany, Belgium, UK and Sweden are eligible if they have a >10 % expected risk to develop islet autoantibodies by age 6 years as determined by HLA DR/DQ genotype, polygenic risk score and family history of type 1 diabetes. A total of 2252 eligible children are randomized 1:1 to COVID-19 vaccine (Comirnaty® 3 μg Omicron XBB.1.5 or future new variants) or placebo (0.9 % Sodium Chloride) administered three times. Children are followed until the minimum age of 2.5 years and maximum age of 6 years. The intervention is accompanied by analyses of immune and metabolic parameters to determine changes induced by viral infections and to investigate mechanisms by which viral infection may lead to islet autoimmunity. The Sponsor is the Klinikum rechts der Isar, Technical University Munich. The study was approved by Clinical Trials Information System (CTIS, EU Trial number: 2023-507348-35-00) and by Integrated Research Application System (IRAS, IRAS-ID: 1009668).

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Contemporary Clinical Trials Communications
volume
44
article number
101434
publisher
Elsevier
external identifiers
  • scopus:85215846365
  • pmid:39916680
ISSN
2451-8654
DOI
10.1016/j.conctc.2025.101434
language
English
LU publication?
yes
additional info
© 2025 The Authors.
id
92404eec-dab6-4485-be64-6e9ad43f3280
date added to LUP
2025-02-27 10:20:24
date last changed
2025-07-04 15:11:57
@article{92404eec-dab6-4485-be64-6e9ad43f3280,
  abstract     = {{<p>Viral infections in the first year of life are associated with islet autoimmunity and type 1 diabetes risk. The Anti-Viral Action against Type 1 Diabetes Autoimmunity (AVAnT1A)- study is a clinical phase IV investigator initiated, randomised, controlled, multicentre, primary prevention trial conducted to determine whether vaccination against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in children with elevated genetic risk. Additionally, it investigates the role of viral infections in the etiology of islet autoimmunity by intense surveillance within the first two years of life. Infants aged 3.00-4.00 months from Germany, Belgium, UK and Sweden are eligible if they have a &gt;10 % expected risk to develop islet autoantibodies by age 6 years as determined by HLA DR/DQ genotype, polygenic risk score and family history of type 1 diabetes. A total of 2252 eligible children are randomized 1:1 to COVID-19 vaccine (Comirnaty® 3 μg Omicron XBB.1.5 or future new variants) or placebo (0.9 % Sodium Chloride) administered three times. Children are followed until the minimum age of 2.5 years and maximum age of 6 years. The intervention is accompanied by analyses of immune and metabolic parameters to determine changes induced by viral infections and to investigate mechanisms by which viral infection may lead to islet autoimmunity. The Sponsor is the Klinikum rechts der Isar, Technical University Munich. The study was approved by Clinical Trials Information System (CTIS, EU Trial number: 2023-507348-35-00) and by Integrated Research Application System (IRAS, IRAS-ID: 1009668).</p>}},
  author       = {{Hummel, Sandra and Käßl, Alexandra and Arnolds, Stefanie and Achenbach, Peter and Berner, Reinhard and Casteels, Kristina and Hyöty, Heikki and Kordonouri, Olga and Larsson, Helena Elding and Lundgren, Markus and Marcovecchio, M Loredana and Owen, Catherine and Pfirrmann, Markus and Robson, Steve and Szadkowska, Agnieszka and Szypowska, Agnieszka and Tree, Timothy and Weiss, Andreas and Ziegler, Anette-Gabriele and Bonifacio, Ezio}},
  issn         = {{2451-8654}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Contemporary Clinical Trials Communications}},
  title        = {{Anti-viral action against type 1 diabetes autoimmunity : The GPPAD-AVAnT1A study protocol}},
  url          = {{http://dx.doi.org/10.1016/j.conctc.2025.101434}},
  doi          = {{10.1016/j.conctc.2025.101434}},
  volume       = {{44}},
  year         = {{2025}},
}